NFKB1 and asthma: Lipoxin receptor agonists such as BML-111 have been shown to suppress key inflammatory processes (e.g., TLR2/MyD88/NF-κB) and reduce cytokine production in a mouse model, further supporting their therapeutic potential in asthma [253].